Misonidazole Reduces Toxicity of Oral CCNU in Mice
Author Information
Author(s): F.Y.F. Lee, P. Workman
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit
Hypothesis
Misonidazole alters the pharmacokinetics of oral CCNU, affecting its antitumor activity and toxicity.
Conclusion
Misonidazole protects normal tissues from the toxicity of oral CCNU while reducing its antitumor activity.
Supporting Evidence
- Misonidazole reduced the antitumor activity of oral CCNU by dose modifying factors of 0.58-0.71.
- Oral CCNU was 1.45 times less toxic to normal tissue compared to the i.p. route.
- The peak plasma CCNU concentration after oral administration was significantly lower than after i.p. administration.
Takeaway
Misonidazole helps protect healthy cells from a cancer drug called CCNU, but it also makes the drug less effective against tumors.
Methodology
Adult male C3H/He mice were treated with oral CCNU and misonidazole, and their tumor response and toxicity were measured.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Adult male C3H/He mice weighing between 25-35 g.
Statistical Information
P-Value
0.01 > P > 0.002
Confidence Interval
(40.1-53.4) for i.p. route; (61.5-69.2) for oral route
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website